Harmony Biosciences Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRMY research report →
About the company
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy.
- CEO
- Jeffrey Dayno
- IPO
- 2020
- Employees
- 268
- HQ
- Plymouth Meeting, PA, US
Price Chart
- Market Cap
- $2.16B
- P/E
- 14.79
- P/S
- 2.40
- P/B
- 2.37
- EV/EBITDA
- 7.60
- Div Yield
- 0.00%
- Gross Margin
- 76.55%
- Op Margin
- 21.08%
- Net Margin
- 16.20%
- ROE
- 17.19%
- ROIC
- 12.50%
- Revenue
- $868.45M · 21.51%
- Net Income
- $158.69M · 9.07%
- EPS
- $2.76 · 7.81%
- Op Income
- $208.47M
- FCF YoY
- 59.09%
- 52W High
- $40.87
- 52W Low
- $25.52
- 50D MA
- $32.46
- 200D MA
- $32.32
- Beta
- 0.97
- Avg Volume
- 842.14K
Get TickerSpark's AI analysis on HRMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Germano Geno J | other | 21,231 |
| May 14, 26 | Germano Geno J | other | 0 |
| May 14, 26 | Szyper Linda M | other | 21,872 |
| May 14, 26 | Philip Ron M | other | 21,872 |
| May 14, 26 | Graf R. Mark | other | 21,872 |
| May 14, 26 | Sabater Juan A. | other | 21,872 |
| May 14, 26 | Sender Gary | other | 21,872 |
| May 1, 26 | Budur Kumar | other | 18,750 |
| May 1, 26 | Budur Kumar | other | 18,750 |
| May 1, 26 | Budur Kumar | other | 8,882 |
Our HRMY coverage
Recent articles, reports, and earnings notes.
No research on HRMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HRMY report →Similar companies
Peers in the same neighborhood.